The A3BC aims to:
- Build world-class interdisciplinary research capacity and facilitate training of the next generation of rheumatology/MSK clinician (medical, nursing, allied health etc.) and basic science researchers.
- Facilitate growth of our future MSK research workforce and outputs so Australia will become more attractive as a research partner internationally.
- Produce research outcomes that will enable improvements in the outcomes of children and adults with rheumatic diseases through effective translation of research into clinical practice and policy.
The A3BC team are actively seeking significant funding from government, industry and philanthropy to invest in supporting and attracting early to mid-career researchers, provide an outstanding research environment for them to thrive, and support them with active and nuanced mentoring to optimise their career progression.
The A3BC headquarters (and lead adult site) are based at the Institute of Bone and Joint Research, a division of the Kolling Institute of Medical Research in Sydney (within the Royal North Shore Hospital precinct), however this is a truly national project and the PI team represent the leading rheumatology research institutes across Australia. The Murdoch Children’s Research Institute (MCRI) will lead the paediatric component of the A3BC and will harness the exceptional MCRI research precinct opportunities for students and post-doctoral researchers. Other key Institutes and Departments include the University of Sydney, NSW Health Pathology Statewide Biobank, Diamantina Institute, University of Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Basil Hetzel Institute/The Queen Elizabeth Hospital, Flinders Medical Centre, and Harry Perkins Institute of Medical Research.
Through our seed philanthropic funding, the A3BC will support its workforce to plan and execute outstanding research through upgrading current facilities with cutting-edge equipment, nation-leading SOPs to practice under, and a highly sophisticated national online data system to connect all investigators and bring together several datasets for a new (and necessary) level of holistic study design and analyses.
To make impactful discoveries and translate outputs from our research to improved outcomes for children and adults with rheumatic diseases it is clear there needs to be multidisciplinary, multi-site collaboration at national and international levels – the more we share, the more we have. This includes between researchers, clinicians, health/data organisations, technology partners, consumer advocacy groups and people with rheumatic diseases. The importance of collaboration is distilled in the foundations of the development of the A3BC, with most national clinicians and researchers engaged in detailed consultation regarding the scope and vision of the project. A3BC members represent all the main MSK/arthritis research institutes in Australia as well as key teaching hospitals, local health districts, private practices, universities, specialty medical colleges, State and Commonwealth government, consumer peak bodies, policy groups and the newly formed Advanced Health Research and Translational Centres. This has precipitated in the A3BC being comprised of 8 national biobank nodes, over 60 national principal and associate clinician/researcher investigators, over 40 participating public and private hospital/clinic sites and nearly 20 leading research organisations!